Research and application of liquid biopsy based on epigenetic markers in the diagnosis and treatment of solid tumors

doi:10.3760/cma.j.cn371439-20200918-00068

Abstract

Abstract:

Epigenetic changes are closely related to carcinogenesis, tumor progression and prognosis, which have a considerable potential in assisting the precision and minimally invasive management of cancers. The progress of detection techniques for DNA methylation, hydroxymethylation and histone modification has promoted the research works of liquid biopsy targeting epigenetic markers, and recently, important progress has been made in tumor location, early diagnosis, clinical staging, evaluation of treatment response, monitoring of recurrence and prognostic prediction of solid tumors.

Key words: Neoplasms, Biomarkers,tumor, Epigenomics, Liquid biopsy

Zhuang Weitao, Qiao Guibin. Research and application of liquid biopsy based on epigenetic markers in the diagnosis and treatment of solid tumors[J]. Journal of International Oncology, 2021, 48(6): 358-361.

References 30

[1]	U.S. Food and Drug Administration. FDA approves first liquid biopsy next-generation sequencing companion diagnostic test[EB/OL].[2020-08-11]. https://www.fda.gov/news-events/press-announcements/fda-approves-first-liquid-biopsy-next-generation-sequencing-companion-diagnostic-test.
[2]	Kang S, Li Q, Chen Q, et al. CancerLocator: non-invasive cancer diagnosis and tissue-of-origin prediction using methylation profiles of cell-free DNA[J]. Genome Biol, 2017,18(1):53. DOI: 10.1186/s13059-017-1191-5. doi: 10.1186/s13059-017-1191-5
[3]	Jensen SØ, Øgaard N, Ørntoft MW, et al. Novel DNA methylation biomarkers show high sensitivity and specificity for blood-based detection of colorectal cancer-a clinical biomarker discovery and validation study[J]. Clin Epigenetics, 2019,11(1):158. DOI: 10.1186/s13148-019-0757-3. doi: 10.1186/s13148-019-0757-3
[4]	Chen X, Gole J, Gore A, et al. Non-invasive early detection of cancer four years before conventional diagnosis using a blood test[J]. Nat Commun, 2020,11(1):3475. DOI: 10.1038/s41467-020-17316-z. doi: 10.1038/s41467-020-17316-z
[5]	Widschwendter M, Zikan M, Wahl B, et al. The potential of circula-ting tumor DNA methylation analysis for the early detection and management of ovarian cancer[J]. Genome Med, 2017,9(1):116. DOI: 10.1186/s13073-017-0500-7. doi: 10.1186/s13073-017-0500-7 pmid: 29268796
[6]	Sheaffer KL, Elliott EN, Kaestner KH. DNA hypomethylation contributes to genomic instability and intestinal cancer initiation[J]. Cancer Prev Res (Phila), 2016,9(7):534-546. DOI: 10.1158/1940-6207.CAPR-15-0349. doi: 10.1158/1940-6207.CAPR-15-0349 pmid: 26883721
[7]	Margalit S, Avraham S, Shahal T, et al. 5-Hydroxymethylcytosine as a clinical biomarker: fluorescence-based assay for high-throughput epigenetic quantification in human tissues[J]. Int J Cancer, 2020,146(1):115-122. DOI: 10.1002/ijc.32519. doi: 10.1002/ijc.32519 pmid: 31211411
[8]	Pfeifer GP, Szabó PE. Gene body profiles of 5-hydroxymethylcytosine: potential origin, function and use as a cancer biomarker[J]. Epigenomics, 2018,10(8):1029-1032. DOI: 10.2217/epi-2018-0066. doi: 10.2217/epi-2018-0066 pmid: 30052061
[9]	Zeng C, Stroup EK, Zhang Z, et al. Towards precision medicine: advances in 5-hydroxymethylcytosine cancer biomarker discovery in liquid biopsy[J]. Cancer Commun (Lond), 2019,39(1):12. DOI: 10.1186/s40880-019-0356-x.
[10]	Li D, Zeng Z. Epigenetic regulation of histone H3 in the process of hepatocellular tumorigenesis[J]. Biosci Rep, 2019, 39(8): BSR20191815. DOI: 10.1042/BSR20191815.
[11]	Chrun ES, Modolo F, Daniel FI. Histone modifications: a review about the presence of this epigenetic phenomenon in carcinogenesis[J]. Pathol Res Pract, 2017,213(11):1329-1339. DOI: 10.1016/j.prp.2017.06.013. doi: 10.1016/j.prp.2017.06.013
[12]	Li YH, Li YX, Li M, et al. The Ras-ERK1/2 signaling pathway regulates H3K9ac through PCAF to promote the development of pancreatic cancer[J]. Life Sci, 2020,256:117936. DOI: 10.1016/j.lfs.2020.117936. doi: 10.1016/j.lfs.2020.117936
[13]	Chae YK, Davis AA, Jain S, et al. Concordance of genomic alterations by next-generation sequencing in tumor tissue versus circulating tumor DNA in breast cancer[J]. Mol Cancer Ther, 2017,16(7):1412-1420. DOI: 10.1158/1535-7163.MCT-17-0061. doi: 10.1158/1535-7163.MCT-17-0061
[14]	Guo Q, Wang J, Xiao J, et al. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing[J]. Mol Cancer, 2018,17(1):131. DOI: 10.1186/s12943-018-0875-0. doi: 10.1186/s12943-018-0875-0
[15]	Huang J, Wang L. Cell-free DNA methylation profiling analysis-technologies and bioinformatics[J]. Cancers (Basel), 2019,11(11):1741. DOI: 10.3390/cancers11111741. doi: 10.3390/cancers11111741
[16]	Shen SY, Singhania R, Fehringer G, et al. Sensitive tumour detection and classification using plasma cell-free DNA methylomes[J]. Nature, 2018,563(7732):579-583. DOI: 10.1038/s41586-018-0703-0. doi: 10.1038/s41586-018-0703-0 pmid: 30429608
[17]	Shen SY, Burgener JM, Bratman SV, et al. Preparation of cfMeDIP-seq libraries for methylome profiling of plasma cell-free DNA[J]. Nat Protoc, 2019,14(10):2749-2780. DOI: 10.1038/s41596-019-0202-2. doi: 10.1038/s41596-019-0202-2 pmid: 31471598
[18]	Song CX, Szulwach KE, Fu Y, et al. Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine[J]. Nat Biotechnol, 2011,29(1):68-72. DOI: 10.1038/nbt.1732. doi: 10.1038/nbt.1732
[19]	Song CX, Yin S, Ma L, et al. 5-Hydroxymethylcytosine signatures in cell-free DNA provide information about tumor types and stages[J]. Cell Res, 2017,27(10):1231-1242. DOI: 10.1038/cr.2017.106. doi: 10.1038/cr.2017.106
[20]	Zeng H, He B, Xia B, et al. Bisulfite-free, nanoscale analysis of 5-Hydroxymethylcytosine at single base resolution[J]. J Am Chem Soc, 2018,140(41):13190-13194. DOI: 10.1021/jacs.8b08297. doi: 10.1021/jacs.8b08297
[21]	Yuan F, Yu Y, Zhou YL, et al. 5hmC-MIQuant: ultrasensitive quantitative detection of 5-hydroxymethylcytosine in low-input cell-free DNA samples[J]. Anal Chem, 2020,92(1):1605-1610. DOI: 10.1021/acs.analchem.9b04920. doi: 10.1021/acs.analchem.9b04920
[22]	Reddy D, Khade B, Pandya R, et al. A novel method for isolation of histones from serum and its implications in therapeutics and prognosis of solid tumours[J]. Clin Epigenetics, 2017,9:30. DOI: 10.1186/s13148-017-0330-x. doi: 10.1186/s13148-017-0330-x
[23]	Hlady RA, Zhao X, Pan X, et al. Genome-wide discovery and validation of diagnostic DNA methylation-based biomarkers for hepatocellular cancer detection in circulating cell free DNA[J]. Theranostics, 2019,9(24):7239-7250. DOI: 10.7150/thno.35573. doi: 10.7150/thno.35573 pmid: 31695765
[24]	Nassiri F, Chakravarthy A, Feng S, et al. Detection and discrimination of intracranial tumors using plasma cell-free DNA methylomes[J]. Nat Med, 2020,26(7):1044-1047. DOI: 10.1038/s41591-020-0932-2. doi: 10.1038/s41591-020-0932-2
[25]	Nuzzo PV, Berchuck JE, Korthauer K, et al. Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes[J]. Nat Med, 2020,26(7):1041-1043. DOI: 10.1038/s41591-020-0933-1. doi: 10.1038/s41591-020-0933-1
[26]	Ko JMY, Ng HY, Lam KO, et al. Liquid biopsy serial monitoring of treatment responses and relapse in advanced esophageal squamous cell carcinoma[J]. Cancers (Basel), 2020,12(6):1352. DOI: 10.3390/cancers12061352. doi: 10.3390/cancers12061352
[27]	Lehmann-Werman R, Neiman D, Zemmour H, et al. Identification of tissue-specific cell death using methylation patterns of circulating DNA[J]. Proc Natl Acad Sci U S A, 2016,113(13):E1826-E1834. DOI: 10.1073/pnas.1519286113. doi: 10.1073/pnas.1519286113
[28]	Barault L, Amatu A, Siravegna G, et al. Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer[J]. Gut, 2018,67(11):1995-2005. DOI: 10.1136/gutjnl-2016-313372. doi: 10.1136/gutjnl-2016-313372
[29]	Duruisseaux M, Martínez-Cardús A, Calleja-Cervantes ME, et al. Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis[J]. Lancet Respir Med, 2018,6(10):771-781. DOI: 10.1016/S2213-2600(18)30284-4. doi: S2213-2600(18)30284-4 pmid: 30100403
[30]	Jensen LH, Olesen R, Petersen LN, et al. NPY gene methylation as a universal, longitudinal plasma marker for evaluating the clinical benefit from last-line treatment with regorafenib in metastatic colorectal cancer[J]. Cancers (Basel), 2019,11(11):1649. DOI: 10.3390/cancers11111649. doi: 10.3390/cancers11111649